Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
imPaCT-PRO
2024-520043-17-00Phase 3Authorised
- Sponsor
- Institute of Molecular Medicine and Biomedical Research
- Start
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tinzaparin in pancreatic cancer (PC) (2 arms), sponsored by Institute of Molecular Medicine and Biomedical Research. Primary endpoints: Progression-free survival (PFS) and Venous thromboembolism (VTE) events. Planned start Jan 2025; status: authorised.
02
Drugs
tinzaparin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2024-520043-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520043-17-00.